NCT03424005: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)

NCT03424005
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Symptomatic, untreated, or actively progressing CNS metastases may be excluded from stage 2 of the study
https://ClinicalTrials.gov/show/NCT03424005

Comments are closed.

Up ↑